Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases

Khanna, Dinesh; Agrawal, Harsh; Clements, Philip J.

doi:10.1093/rheumatology/keq062

Cited by 52 publications

(20 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The choice is not based in clinical guidelines and the more common agent is Methotrexate [4]. Other drug-regimens described in small cases series with variables results are: anti-TNF including Etanercept [5,6], azathioprine or cyclosporine. Our patient evolved with a corticosteroid refractory disease characterized by a predominantly articular involvement associated to major inflammatory response.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Tocilizumab in the treatment of Eosinophilic fasciitis: Report of one case

2015

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Efficacy of Tocilizumab in the treatment of Eosinophilic fasciitis: Report of one case

2015

View full text Add to dashboard Cite

“…Infliximab (chimeric monoclonal antibody to TNF‐α) has induced remission in one case of generalized morphoea and three cases of eosinophilic fasciitis . As a Th1 cytokine linked to the early inflammatory phase of morphoea, one can elucidate how TNF‐α inhibition could be a useful therapy.…”

Section: Implications For Therapymentioning

confidence: 99%

The molecular pathogenesis of morphoea: from genetics to future treatment targets

2017

View full text Add to dashboard Cite

Summary A number of immunoinflammatory and profibrotic mechanisms are recognized in the pathogenesis of broad sclerotic skin processes and, more specifically, morphoea. However, the precise aetiopathogenesis is complex and remains unclear. Morphoea is clinically heterogeneous, with variable anatomical patterning, depth of tissue involvement and sclerotic, inflammatory, atrophic and dyspigmented morphology. Underlying mechanisms determining these reproducible clinical subsets are poorly understood but of great clinical and therapeutic relevance. Regional susceptibility mechanisms (e.g. environmental triggers, mosaicism and positional identity) together with distinct pathogenic determinants (including innate, adaptive and imbalanced pro‐ and antifibrotic signalling pathways) are likely implicated. In the age of genetic profiling and personalized medicine, improved characterization of the environmental, systemic, local, genetic and immunopathological factors underpinning morphoea pathogenesis may open the door to novel targeted therapeutic approaches.

show abstract

“…Histologic findings in our patient also showed abundant eosinophils and thickened fascia. In a review of the literature, only one of the DPM cases mentioned eosinophils on biopsy (21), whereas all except three EF cases showed eosinophils on biopsy (22)(23)(24). Lastly, although peripheral eosinophil count has been reported to be a surrogate marker for disease activity in EF, it has never been reported in DPM.…”

Section: Case Reportmentioning

confidence: 99%

Pansclerotic Morphea with Features of Eosinophilic Fasciitis: Distinct Entities or Part of a Continuum?

Odhav

Hoeltzel

Canty

2014

Pediatric Dermatology

View full text Add to dashboard Cite

Scleroderma is a highly complex disorder in its clinical manifestations and pathogenesis. It has a wide range of clinical manifestations due to varying degrees of vasculopathy, autoimmunity, altered endothelium function, and abnormal fibrosis. The most widely used classification system grouped eosinophilic fasciitis and disabling pansclerotic morphea of childhood into the category of deep morphea. This previous classification does not include a category for overlapping conditions. A proposed new classification includes a new mixed subtype in which a combination of two or more of the previous subtypes is present in the same individual, although eosinophilic fasciitis has been excluded. We present the case of a 4-year-old boy who presented with features of disabling pansclerotic morphea and eosinophilic fasciitis simultaneously, which to our knowledge has not been previously reported. This suggests that these diseases are part of a more closely related continuum rather than separate disorders, as currently classified.

show abstract

Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases

Abstract: Based on this and other reported cases, infliximab may be beneficial in patients with steroid-resistant EF.

Cited by 52 publications

References 17 publications

Efficacy of Tocilizumab in the treatment of Eosinophilic fasciitis: Report of one case

Efficacy of Tocilizumab in the treatment of Eosinophilic fasciitis: Report of one case

The molecular pathogenesis of morphoea: from genetics to future treatment targets

Pansclerotic Morphea with Features of Eosinophilic Fasciitis: Distinct Entities or Part of a Continuum?

Contact Info

Product

Resources

About